Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2020

Open Access 01-12-2020 | Research Article

Comparison of Bayesian and frequentist group-sequential clinical trial designs

Authors: Nigel Stallard, Susan Todd, Elizabeth G. Ryan, Simon Gates

Published in: BMC Medical Research Methodology | Issue 1/2020

Login to get access

Abstract

Background

There is a growing interest in the use of Bayesian adaptive designs in late-phase clinical trials. This includes the use of stopping rules based on Bayesian analyses in which the frequentist type I error rate is controlled as in frequentist group-sequential designs.

Methods

This paper presents a practical comparison of Bayesian and frequentist group-sequential tests. Focussing on the setting in which data can be summarised by normally distributed test statistics, we evaluate and compare boundary values and operating characteristics.

Results

Although Bayesian and frequentist group-sequential approaches are based on fundamentally different paradigms, in a single arm trial or two-arm comparative trial with a prior distribution specified for the treatment difference, Bayesian and frequentist group-sequential tests can have identical stopping rules if particular critical values with which the posterior probability is compared or particular spending function values are chosen. If the Bayesian critical values at different looks are restricted to be equal, O’Brien and Fleming’s design corresponds to a Bayesian design with an exceptionally informative negative prior, Pocock’s design to a Bayesian design with a non-informative prior and frequentist designs with a linear alpha spending function are very similar to Bayesian designs with slightly informative priors.This contrasts with the setting of a comparative trial with independent prior distributions specified for treatment effects in different groups. In this case Bayesian and frequentist group-sequential tests cannot have the same stopping rule as the Bayesian stopping rule depends on the observed means in the two groups and not just on their difference. In this setting the Bayesian test can only be guaranteed to control the type I error for a specified range of values of the control group treatment effect.

Conclusions

Comparison of frequentist and Bayesian designs can encourage careful thought about design parameters and help to ensure appropriate design choices are made.
Literature
1.
go back to reference Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Boca Raton: Chapman & Hall; 2000. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Boca Raton: Chapman & Hall; 2000.
2.
go back to reference Berry SM, Carlin BP, Lee JJ, Müller P. Bayesian Adaptive Methods for Clinical Trials. Boca Raton: CRC Press; 2011. Berry SM, Carlin BP, Lee JJ, Müller P. Bayesian Adaptive Methods for Clinical Trials. Boca Raton: CRC Press; 2011.
3.
go back to reference Zhu H, Yu Q. A Bayesian sequential design using alpha spending function to control type I error. Stat Methods Med Res. 2017; 26:2184–69.CrossRef Zhu H, Yu Q. A Bayesian sequential design using alpha spending function to control type I error. Stat Methods Med Res. 2017; 26:2184–69.CrossRef
4.
go back to reference Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials. J R Stat Soc Ser A. 1994; 157:357–416.CrossRef Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials. J R Stat Soc Ser A. 1994; 157:357–416.CrossRef
5.
go back to reference Ryan EG, Bruce J, Metcalfe AJ, Stallard N, Lamb SE, Viele K, Young D, Gates S. Using Bayesian adaptive designs to improve phase III trials: a respiratory care example. BMC Med Res Methodol. 2019; 19:99.CrossRef Ryan EG, Bruce J, Metcalfe AJ, Stallard N, Lamb SE, Viele K, Young D, Gates S. Using Bayesian adaptive designs to improve phase III trials: a respiratory care example. BMC Med Res Methodol. 2019; 19:99.CrossRef
7.
go back to reference Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PDR, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SPL. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012; 61:1693–700.CrossRef Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PDR, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SPL. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012; 61:1693–700.CrossRef
8.
go back to reference Gsponer T, Gerber F, Bornkamp G, Ohlssen D, Vandemeulebroecke M, Schmidli H. A practical guide to Bayesian group sequential designs. Pharm Stat. 2014; 13:71–80.CrossRef Gsponer T, Gerber F, Bornkamp G, Ohlssen D, Vandemeulebroecke M, Schmidli H. A practical guide to Bayesian group sequential designs. Pharm Stat. 2014; 13:71–80.CrossRef
10.
go back to reference Wilber DJ, Pappone C, Neuzil P, Paola AD, Marchlinski F, Natale A, Macle L, Daoud EG, Calkins H, Hall B, Reddy V, Augello G, Reynolds MR, Vinekar C, Liu CY, Berry SM, Berry DA. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation. J Am Med Assoc. 2010; 303:333–40.CrossRef Wilber DJ, Pappone C, Neuzil P, Paola AD, Marchlinski F, Natale A, Macle L, Daoud EG, Calkins H, Hall B, Reddy V, Augello G, Reynolds MR, Vinekar C, Liu CY, Berry SM, Berry DA. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation. J Am Med Assoc. 2010; 303:333–40.CrossRef
11.
go back to reference Emerson SS, Kittelson JM, Gillen DL. Bayesian evaluation of group sequential clinical trial designs. Stat Med. 2007; 26:1431–49.CrossRef Emerson SS, Kittelson JM, Gillen DL. Bayesian evaluation of group sequential clinical trial designs. Stat Med. 2007; 26:1431–49.CrossRef
12.
go back to reference Emerson SS, Kittelson JM, Gillen DL. Frequentist evaluation of group sequential clinical trial designs. Stat Med. 2007; 26:5047–80.CrossRef Emerson SS, Kittelson JM, Gillen DL. Frequentist evaluation of group sequential clinical trial designs. Stat Med. 2007; 26:5047–80.CrossRef
13.
go back to reference Campbell G. Similarities and differences of Bayesian designs and adaptive designs for medical devices: a regulatory view. Stat Biopharm Res. 2013; 5:356–68.CrossRef Campbell G. Similarities and differences of Bayesian designs and adaptive designs for medical devices: a regulatory view. Stat Biopharm Res. 2013; 5:356–68.CrossRef
15.
go back to reference Bernado JM, Smith AFM. Bayesian Theory. Chichester: Wiley; 2000. Bernado JM, Smith AFM. Bayesian Theory. Chichester: Wiley; 2000.
16.
go back to reference Jennison C, Turnbull BW. Group sequential analysis incorporting covariate information. J Am Stat Assoc. 1997; 92:1330–41.CrossRef Jennison C, Turnbull BW. Group sequential analysis incorporting covariate information. J Am Stat Assoc. 1997; 92:1330–41.CrossRef
17.
go back to reference Saville BR, Connor JT, Ayers GD, Alvarez J. The utility of Bayesian predictive probabilities for interim monitoring of clinical trials. Clin Trials. 2014; 11:485–93.CrossRef Saville BR, Connor JT, Ayers GD, Alvarez J. The utility of Bayesian predictive probabilities for interim monitoring of clinical trials. Clin Trials. 2014; 11:485–93.CrossRef
18.
go back to reference Mujagic E, Zwimpfer T, Marti WR, Zwahlen M, Hoffmann H, Kindler C, Fux C, Misteli H, Iselin L, Lugli AK, Nebiker CA, von Holzen U, Vinzens F, von Strauss M, Reck S, Kraljević M, Widmer AF, Oertli D, Rosenthal R, Weber WP. Evaluating the optimal timing of surgical antimicrobial prophylaxis: study protocol for a randomized controlled trial. Trials. 2014; 15:188.CrossRef Mujagic E, Zwimpfer T, Marti WR, Zwahlen M, Hoffmann H, Kindler C, Fux C, Misteli H, Iselin L, Lugli AK, Nebiker CA, von Holzen U, Vinzens F, von Strauss M, Reck S, Kraljević M, Widmer AF, Oertli D, Rosenthal R, Weber WP. Evaluating the optimal timing of surgical antimicrobial prophylaxis: study protocol for a randomized controlled trial. Trials. 2014; 15:188.CrossRef
19.
go back to reference Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977; 64:191–9.CrossRef Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977; 64:191–9.CrossRef
20.
go back to reference O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979; 35:549–56.CrossRef O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979; 35:549–56.CrossRef
22.
go back to reference Slud EV, Wei LJ. Two-sample repeated significance tests based on the modified Wilcoxon statistics. J Am Stat Assoc. 1982; 77:862–8.CrossRef Slud EV, Wei LJ. Two-sample repeated significance tests based on the modified Wilcoxon statistics. J Am Stat Assoc. 1982; 77:862–8.CrossRef
23.
go back to reference Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983; 70:659–63.CrossRef Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983; 70:659–63.CrossRef
24.
go back to reference Proschan M, Lan KKG, Wittes JT. Statistical Monitoring of Clinical Trials: A Unified Approach. New York: Springer; 2006. Proschan M, Lan KKG, Wittes JT. Statistical Monitoring of Clinical Trials: A Unified Approach. New York: Springer; 2006.
25.
go back to reference Kim K, DeMets DL. Design and analysis of group sequential tests based on the type I error spending rate function. Biometrika. 1987; 74:149–54.CrossRef Kim K, DeMets DL. Design and analysis of group sequential tests based on the type I error spending rate function. Biometrika. 1987; 74:149–54.CrossRef
27.
go back to reference Jennison C, Turnbull BW. Exact calculations for sequential t, χ 2 and F tests. Biometrika. 1991; 78:133–41. Jennison C, Turnbull BW. Exact calculations for sequential t, χ 2 and F tests. Biometrika. 1991; 78:133–41.
28.
go back to reference Stallard N, Todd S. Exact sequential tests for single samples of discrete responses using spending functions. Stat Med. 2000; 19:3051–64.CrossRef Stallard N, Todd S. Exact sequential tests for single samples of discrete responses using spending functions. Stat Med. 2000; 19:3051–64.CrossRef
29.
go back to reference Stallard N, Rosenberger WF. Exact group-sequential designs for clinical trials with randomized play-the-winner allocation. Stat Med. 2002; 21:467–80.CrossRef Stallard N, Rosenberger WF. Exact group-sequential designs for clinical trials with randomized play-the-winner allocation. Stat Med. 2002; 21:467–80.CrossRef
30.
go back to reference Cui L, Hung HMJ, Wang S-J. Modification of sample size in group sequential clinical trials. Biometrics. 1999; 55:853–7.CrossRef Cui L, Hung HMJ, Wang S-J. Modification of sample size in group sequential clinical trials. Biometrics. 1999; 55:853–7.CrossRef
31.
go back to reference Pocock S, White I. Trials stopped early: too good to be true?Lancet. 1999; 353:943–4.CrossRef Pocock S, White I. Trials stopped early: too good to be true?Lancet. 1999; 353:943–4.CrossRef
Metadata
Title
Comparison of Bayesian and frequentist group-sequential clinical trial designs
Authors
Nigel Stallard
Susan Todd
Elizabeth G. Ryan
Simon Gates
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2020
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/s12874-019-0892-8

Other articles of this Issue 1/2020

BMC Medical Research Methodology 1/2020 Go to the issue